XAIR
A little more staying power
Beyond Air’s subsidiary Beyond Cancer just brought updated Phase 1 UNO data to AACR 2026, and the headline is basically: the signal is still alive. The company says heavily pre-treated patients continued to show survival follow-up after a single intratumoral UNO injection, which is the kind of early-stage biotech phrase that sounds like it belongs in a sci-fi trailer — but it matters because durability is the whole game here.
Why investors should care
Early cancer programs can disappear faster than a free office donut. So when a company says its safety and survival data are still holding up, that’s a step toward credibility, not a victory lap. It doesn’t prove UNO works — Phase 1 is still the “does this explode?” chapter, not the “get ready for launch” chapter — but it does keep the story moving in the right direction.
Not just science, also legal armor
Beyond Air also said it received a U.S. patent allowance covering proprietary gas-delivery technology tied to UNO. That’s not the same as a commercial moat, but patents are still the biotech version of putting a fence around your backyard before the neighbors start copy-pasting your idea.
Big picture: this is still a tiny-data, high-hope oncology story. But in biotech, “still looks alive” is often enough to keep investors paying attention.